Chloroplasts: Transforming Biopharmaceutical Manufacturing - The primary development model for producing human recombinant proteins in tobacco is based on green tissue (leaf) biomass processing. - Bi

ADVERTISEMENT

Chloroplasts: Transforming Biopharmaceutical Manufacturing
The primary development model for producing human recombinant proteins in tobacco is based on green tissue (leaf) biomass processing.


BioPharm International



Karen K. Oishi
Since the 1980s, the use of human proteins to treat and cure diseases has comprised an increasingly significant sector of the pharmaceutical industry. In 2003, an estimated $39 billion of protein therapeutics were sold in the US. In the next ten years, domestic sales of protein pharmaceuticals are estimated to grow to $359 billion.1

While traditional drugs are chemically synthesized, living organisms produce therapeutic proteins. The current generation of microbial and mammalian cell bioreactor-based systems will not be able to handle future demand. Expensive small-capacity units are too big a financial burden to produce and operate in the quantities needed. Manufacturing systems that use plants as bioreactors can meet the growing demand of the healthcare industry for therapeutic proteins at far lower cost.

Plant chloroplast transformation technology (CTT) can deliver quality proteins at low cost. Several of the advantages of this production platform are listed in Table 1. CTT in tobacco is now being validated as we explain below.


Photo courtesy of the Kentucky Research and Development Center, University of Kentucky, Lexington, KY.
Chloroplasts Green plant cells contain three distinct genetic entities; a single nuclear genome and two plastomic organelle genomes.2 These organelles are the chloroplast and the mitochondria, each with multiple copies of a circular double-stranded DNA genome. Each organelle contains replication, transcription, translation and processing machinery that is functionally and physically separate from the rest of the cell. Since the late 1980s the light-harvesting chloroplast has been the focus of intense genetic engineering research, which has established that plants with transformed chloroplasts can potentially provide low-cost, stable, quality proteins.3-8

The chloroplast is a metabolic organelle designed to synthesize abundant proteins for energy generation and plant growth and development. The chloroplast's genome is a self-replicating circular double-stranded DNA molecule ranging in size from 110 to 220 kilobase pairs depending on the species of plant. In the majority of plants, the chloroplast genome has two inverted regions.2 With up to 100 genomes per chloroplast and up to 100 chloroplasts per cell, the integration of a transgene through homologous recombination into the inverted repeat region can generate up to 20,000 copies of the transgene per cell.

The chloroplast generates proteins in a manner similar to a prokaryotic cell, creating polycistronic messages and accepting large DNA inserts with multiple genes and repetitive elements without inducing silencing pathways. The chloroplast has been demonstrated to properly fold and assemble disulfide-bonded proteins, which can be sequestered away from cytosolic proteases during growth and development.9 However similar to bacterial expression systems, chloroplasts do not have the post-translational processing machinery for glycosylation of proteins.


Table 1. Chloroplast Transformation Technology Advantages
Source of a Million Seeds As shown in Figure 1, single or multiple genes can be integrated and expressed in transformed chloroplast as polycistronic mRNA. The translational regulatory sequence, or ribosome-binding site (RBS), then directs high levels of target protein synthesis. Dr. Henry Daniell, the technical founder of Chlorogen, developed universal transformation vectors, which direct integration of the transgene to the inverted repeated region of plant chloroplasts by homologous recombination.10

The chloroplast transformation-expression vector is introduced into the chloroplast by particle bombardment of plant tissue, or polyethylene glycol treatment of protoplast.3,8 Transformation is initiated by transgene integration into a few copies of chloroplast genome within a single cell, followed by antibiotic selection and transgene replication during the next 15 to 20 cell divisions, which results in a homogeneous plastid genome population. Integration of the transgene expression cassette into one of the inverted repeat regions will initiate a copy number correction resulting in the duplication and insertion of another transgene cassette into the second inverted repeat region.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

EMA Warns of Falsified Herceptin Vials
April 16, 2014
Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
Author Guidelines
Source: BioPharm International,
Click here